Dosing protocol · Hormone Support
Degarelix dosing & administration
Fast-acting GnRH antagonist that rapidly lowers testosterone for advanced prostate cancer treatment
Suggested dose
80 – 240 mg
137 peptides · 10 goals
Goals
Cognitive
Cosmetic
Growth Hormone
Healing & Recovery
Hormone Support
Immune
Metabolic
Mitochondrial
Sexual Health
Sleep & Recovery
Dosing protocol · Hormone Support
Fast-acting GnRH antagonist that rapidly lowers testosterone for advanced prostate cancer treatment
Suggested dose
80 – 240 mg
Dosing
Subcutaneous
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
2 documented dose levels — separate regimens, not a titration schedule
240 mg (two 120 mg injections)
FDA-approved loading dose for advanced prostate cancer, given as two separate deep injections under the skin of the belly. This rapidly lowers testosterone without the early surge seen with older drugs .
80 mg
FDA-approved maintenance dose, started 28 days after the loading dose. Keeps testosterone at castrate levels in over 97% of patients .
Timing
Best time to take
Use Degarelix at the same time each day for optimal results. Consistency in timing helps maintain stable levels and maximize therapeutic benefits. Follow your healthcare provider's specific instructions.
With food?
Degarelix can generally be used with or without food. If you experience any discomfort, try taking it with a light meal. Follow specific guidance from your healthcare provider.
If stacking
Degarelix should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
Decrease if
Signs of right dose
Administration
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Degarelix in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Degarelix should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: As directed by healthcare provider—rotate sites if applicable
Maintain a consistent schedule for optimal results with Degarelix. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Side effects
Commonly reported: Mild discomfort at treatment site, Injection site pain (28% of patients), Injection site redness or erythema (17%), Hot flashes (26% experience them), Increased liver enzymes and gamma-glutamyltransferase (10%), Weight gain (9%), Hypertension or elevated blood pressure (6%), Back pain (6%), Chills (5%), Constipation (5%), Urinary tract infection (5%), Injection site swelling (6%), Injection site induration or hardness (4%), Decreased sex drive and erectile dysfunction, Gynecomastia (breast tissue growth), Testicular atrophy (shrinking)
Serious side effects
Stop and seek help if
Degarelix should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
Published research
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer (CS21)
Pivotal CS21 trial: degarelix 240 mg subcutaneous starting (loading) dose followed by monthly 80 mg maintenance suppressed testosterone to castrate levels (<0.5 ng/mL) in 97.2% of patients from day 28 to day 364, non-inferior to leuprolide 7.5 mg monthly with faster onset.
FIRMAGON (degarelix for injection) — FDA Prescribing Information
FDA-approved regimen for advanced prostate cancer: starting dose 240 mg given as two 120 mg deep subcutaneous injections (40 mg/mL) into the abdomen; maintenance dose 80 mg (20 mg/mL) subcutaneous every 28 days, first maintenance dose given 28 days after the starting dose.
A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America
Phase II dose-finding study in 127 North American prostate cancer patients: a 200 mg degarelix starting dose induced rapid testosterone suppression (88% at <=0.5 ng/mL by 1 month), sustained over 12 months with 60 or 80 mg monthly maintenance, with no evidence of testosterone surge; degarelix was well tolerated, 5% withdrew for adverse events.
Degarelix: a review of its use in patients with prostate cancer
Review of degarelix (Firmagon/Gonax), approved for prostate cancer in the US, EU and Japan: 240 mg starting dose then 80 mg monthly was non-inferior to leuprolide 7.5 mg monthly for castration, with faster testosterone and PSA suppression and no testosterone surges or microsurges; suppression continued up to 5 years in the trial extension; injection-site reactions and effects of testosterone suppression (hot flushes, weight increase) were the most common adverse events, mostly mild to moderate.
Gonadotropin-releasing hormone: an update review of the antagonists versus agonists
GnRH antagonists act directly to block pituitary GnRH receptors, unlike agonists. Degarelix gives substantially faster onset of castration and faster PSA suppression than leuprolide, with no risk of testosterone surge or clinical flare; other than minor injection-site reactions it is generally well tolerated, with most adverse events consistent with androgen suppression.
Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer
GnRH agonists induce an initial testosterone surge that can cause painful and potentially dangerous clinical flare. Degarelix is a GnRH receptor blocker giving immediate, profound and sustained testosterone reduction without an initial surge; the most common side effects were mild to moderate injection-site reactions and hot flashes.
Adverse effects of androgen deprivation therapy and strategies to mitigate them
Systematic review of androgen deprivation therapy harms: decreased bone mineral density; weight gain, decreased muscle mass and increased insulin resistance; decreased libido and sexual dysfunction; hot flashes; gynecomastia; reduced testicle size; anemia and fatigue. Observational studies also suggest increased risk of diabetes and cardiovascular events.
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer
Prospective 12-month study of 152 men with prostate cancer: men starting androgen deprivation therapy lost 2.5% bone mineral density at the total hip, 2.4% at the trochanter, 2.6% at the total radius, 3.3% total body and 4.0% at the spine over one year, together with a 10.4% increase in total body fat and a 3.5% loss of lean mass; bone loss was maximal in the first year of therapy.
Risks of major long-term side effects associated with androgen-deprivation therapy in men with prostate cancer
Propensity-matched SEER-Medicare cohort of 201,797 men aged 66 years and older with prostate cancer: androgen deprivation therapy was associated with higher risk of bone fracture (HR 1.39), diabetes (HR 1.21), dementia (HR 1.16), coronary heart disease (HR 1.12), acute myocardial infarction (HR 1.11) and sexual dysfunction (HR 1.12) than in men not receiving it.
Androgen deprivation therapy in advanced prostate cancer: insights from a real-world patient survey on health-related quality of life and information and communication sources
Cross-sectional survey of 276 patients on androgen deprivation therapy for advanced prostate cancer: sexual health-related quality of life was low and narrowly distributed, with 84% of patients reporting erectile dysfunction.
The relationship between hot flashes and testosterone recovery after 12 months of androgen suppression for men with localised prostate cancer in the ASCENDE-RT trial
Secondary analysis of 398 men given 12 months of androgen deprivation therapy: hot flashes were reported by 93% and resolved in 99%, at a median 7.6 months after stopping therapy. Median time to testosterone recovery after cessation was 9 months to 5 nmol/L, 13 months to 7.5 nmol/L and 18 months to 10 nmol/L, with recovery rates above 90%.
Drugs@FDA approval history: FIRMAGON (degarelix for injection), NDA 022201
FIRMAGON (degarelix) was approved by the FDA as a new molecular entity under NDA 022201 on 24 December 2008, with subsequent labeling supplements through February 2020.
Head to head
The complete Degarelix research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.